Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics, which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer.

Risk Evaluation and Mitigation Strategies (REMS) are the newest tool of the FDA to help manage and ensure safe drug use. REMS are a particularly important issue for oncology, because a disproportionate number of drugs with complex REMS are used in patients with cancer or hematologic disorders.

Chairman Camp, Ranking Member Levin, and members of the committee, it is an honor to appear before you to discuss the need for comprehensive tax reform.

In the wake of the recent financial crisis, Americans...

Chapter covering the clinical reality and political implications of posttraumatic stress disorder.

This paper provides a simple analytic approach for measuring the burden of carbon pricing and shows how to adjust for the capital income bias contained in the Consumer Expenditure Survey.

This book by Alan Viard and Robert Carroll proposes to completely replace the income tax system with a progressive consumption tax.

When partnering with outside consultants to turn around a school, schools districts must consider how the work is setting schools up for long-term success.

We owe it to ourselves to make sure decisions to regulate access to medical care are based on sound science and a fair and transparent process.